Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AffaMed Signs $145 Million Agreement for China Rights to Ophthalmic Drug

publication date: Jan 4, 2022

Shanghai AffaMed acquired greater China rights to an ophthalmic drug from Korea's Hanmi Pharma in an $145 million agreement. AffaMed will have rights to manufacture, develop and commercialize risuteganib (Luminate®), a first-in-class intravitreal injectable product that targets intermediate Dry Age-related Macular Degeneration and other vitreo-retinal diseases. Hanmi will receive $6 million upfront plus milestones and royalties. In 2020, CBC Group merged two of its portfolio companies, AffaMed and EverInsight Therapeutics, into a single entity under the AffaMed name. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital